logo-loader
viewAIM ImmunoTech Inc.

Hemispherx BioPharma reports positive results on ovarian cancer treatment

Hemispherx BioPharma (NYSE American:HEB) CEO Thomas Equels tells Proactive Investors that the biopharma has made significant progress in the study of its flagship drug Ampligen in treating ovarian cancer.

Equels is presenting at the Planet MicroCap Showcase today, in Las Vegas. A live webcast of the presentation can be viewed here:

https://www.webcaster4.com/Webcast/Page/2059/30408

Quick facts: AIM ImmunoTech Inc.

Price: 2.41 USD

NYSE:AIM
Market: NYSE
Market Cap: $78.62 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc. named herein, including the promotion by the Company of AIM ImmunoTech Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: AIM ImmunoTech hopes to take the battle against COVID-19 to...

AIM ImmunoTech (NYSE: AIM) CEO Thomas Equels joined Proactive New York's Christine Corrado on Skype with news the immuno-pharma company announced they have joined ChinaGoAbroad to bring their experimental drug Ampligen to China. Equels telling Proactive how this drug will try to be a...

on 3/3/20

2 min read